Radionetics Oncology
Julie Selkirk is currently the Executive Director, Biology at Radionetics Oncology, bringing new cell therapies to patients with Bit. Bio's opti-ox cell coding technology. With a background in neuroscience and pharmacology, Julie has held various leadership roles in companies such as Bristol Myers Squibb, Celgene, Vertex Pharmaceuticals, Pfizer, and Neurocrine Biosciences. With a Ph.D. in Cell Biology and Receptor Pharmacology from the University of Leicester, Julie has a strong educational background to support her successful career in the pharmaceutical industry.